Upgrade to FY26 Guidance
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company expects significant increases in revenue and improvements in earnings before interest, tax, depreciation, and amortization compared to the previous year. This guidance upgrade is driven by strong demand for IDT's drug manufacturing services and cost savings exceeding targets. Additionally, IDT received two awards recognizing its excellence in RNA manufacturing at the Asia-Pacific RNA Excellence Awards.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from IDT Australia
- March Quarter Update & Positive FY26 Guidance
- 1HFY26 Results Presentation
- 1HFY26 Results
- 1HFY26 Appendix 4D and Half Year Report
- Q1 FY26 Market Update - Strategic Realignment
Later from IDT Australia
All IDT Australia news releasesFollow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia